Glow Blend vs Klow: what is in each vial, what each component is, and what has (and has not) been studied

What "Glow" and "Klow" mean as peptide blend names#

Glow and Klow are trade names used by research-peptide sellers for fixed mixtures of several peptides in one vial. They are not scientific names, they are not defined by any regulator or pharmacopeia, and neither appears in the peer-reviewed literature as the name of a studied mixture. Two sellers can use the same name for vials with different contents or different amounts, so the name tells you which family of products you are looking at and nothing more. What counts is the component list, the amount of each component, and the lot's test report.

On Renuvia's catalog the difference is simple. The Glow Blend product page lists three peptides: BPC-157, TB-500 and GHK-Cu. The Klow product page lists the same three plus a fourth, KPV. Everything else on this page follows from that one difference.

Glow peptide blend vs Klow: composition side by side#

Glow Blend's amounts are stated on its listing: 10 mg BPC-157, 10 mg TB-500 and 50 mg GHK-Cu, for 70 mg in total. Klow is listed as 80 mg in total. The amount of each component in Renuvia's Klow lots has not yet been confirmed; the listing says it will be stated with each lot's Certificate of Analysis, and this page does not give a split until then.

The components and their primary sources#

BPC-157#

BPC-157 is a pentadecapeptide, a chain of fifteen amino acids, whose sequence comes from a larger protein first isolated from human gastric juice. Most of its literature uses rat and mouse injury models of tendon, ligament, muscle, bone and gut. A 2025 systematic review of its orthopaedic research counted 35 preclinical studies and a single human case series and rated the evidence as low-level.^[1] A frequently cited cell study measured outgrowth, survival and migration of rat tendon fibroblasts exposed to the peptide.^[2] In its 2026 review for the compounding bulks list, the FDA found five small, short human studies with limited safety reporting and concluded that its evaluation weighed against listing BPC-157.^[3] An FDA advisory committee later voted to recommend listing it; that vote is nonbinding (see the regulatory section below).

TB-500#

TB-500 is a seven-residue peptide with an acetyl group on its first amino acid, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. A 2012 anti-doping study used liquid chromatography with high-resolution mass spectrometry to identify this N-terminally acetylated 17–23 fragment of thymosin β4 in a product sold as TB-500, then synthesized it to confirm the identification.^[4] The fragment is not the same molecule as full-length thymosin β4, and research on the full protein cannot be assumed to apply to it. The FDA's 2026 briefing identified no human clinical, pharmacokinetic or safety data for TB-500.^[5]

GHK-Cu#

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first reported in human serum. In a 1988 cell study, human fibroblast cultures exposed to GHK-Cu secreted more collagen without a change in cell number.^[6] A 2018 review describes later animal wound work, gene-expression analyses and small studies of topical cosmetic products in people.^[7] It is the largest component by mass in Glow Blend. Our GHK-Cu research summary covers its identifiers and studies in more detail, and the GHK-Cu product page lists the single-peptide vial.

KPV (Klow only)#

KPV is the tripeptide Lys-Pro-Val, the last three residues of alpha-melanocyte-stimulating hormone. Two 2008 papers studied it in cultured intestinal cells and mouse colitis models: one measured its uptake by the peptide transporter PepT1 and inflammatory signaling in the cells,^[8] and the other measured inflammatory readouts in mouse colitis and asked whether the effect depended on the melanocortin-1 receptor.^[9] There are no published human studies. The KPV product page lists the single-peptide vial.

Has either combination been studied?#

No. No published study has examined Glow Blend's three-peptide mixture or Klow's four-peptide mixture, at these amounts or at any other ratio. All of the research in the table belongs to the individual peptides, studied one at a time, mostly in cells and animals.

The only published experiment that tested any two of these components together is a 2026 rat Achilles-tendon study. Thirty-two rats with a repaired tendon were split into four groups: control, BPC-157, TB-500, and both together. The authors measured load to failure, histology scores and collagen staining, and reported that the combined group showed no additional effect on these measures compared with either peptide alone.^[10] That is a two-peptide result in rats. It says nothing about GHK-Cu or KPV in a mixture, and nothing about any effect in people.

• No study of the Glow (BPC-157, TB-500, GHK-Cu) mixture.
• No study of the Klow (BPC-157, TB-500, GHK-Cu, KPV) mixture.
• No data on whether the components interact, chemically or biologically, when combined in one vial.
• None of the four components is an FDA-approved drug.

Regulatory status of the components#

The FDA's list of bulk drug substances that may present significant safety risks in compounding names all four components in the section for substances that were nominated and then withdrawn. The stated concerns are limited or no safety information for BPC-157, no human exposure data for the TB-500 fragment or for KPV, and a possible immunogenicity risk with limited human data for injectable GHK-Cu.^[11] On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500 and KPV to the 503A bulks list. Committee votes are nonbinding, and a substance is added only through formal rulemaking.^[12] BPC-157 and TB-500 are also prohibited in sport under the WADA 2026 Prohibited List.^[13]

How a multi-peptide vial is tested#

A blend is made by combining the peptides in a set proportion and freeze-drying the mixture as one cake, so the components cannot be told apart by eye or by weight. Only analysis can say what is in the vial and in what proportion. Our explainer on peptide blends covers the method in detail; the short version is that a blend raises one identity question and one quantity question per component, plus the question of whether the ratio matches the label.

Glow Blend and Klow make that harder than a two-peptide blend. GHK-Cu is a copper complex, so its identity has a peptide part and a copper part. The components also differ greatly in size and amount: in Glow Blend, GHK-Cu is five times the mass of each of the other two, and a small component can be hard to resolve beside a large one on a chromatogram.

What a Glow Blend or Klow COA should show#

1. Identity of each component. A mass-spectrometry confirmation for every peptide listed: three for Glow Blend, four for Klow. A report that confirms only the largest component has not tested the whole vial.
2. Ideally, the amount of each component. The measured amount, or at least the measured ratio, against the label. A single purity figure for the whole vial does not show whether the components are present in the stated proportion.
3. A chromatogram with assigned peaks, so each peak is matched to its component, with any co-eluting peaks stated.
4. Copper characterization for GHK-Cu, or a statement that only the peptide part was measured.
5. The lot number on the vial, the method, the laboratory and the date.

The COA library lists every Renuvia lot of both blends with its current testing status, marked pending until the laboratory issues the report. The single-peptide vials are on the BPC-157, TB-500, GHK-Cu and KPV product pages.